How Omics-as-a-Service is 
accelerating translational medicine

In the era of data-driven science, translational medicine faces both a great opportunity and a growing challenge: how to turn complex biological information into meaningful, clinical-grade insight — quickly, reliably, and at scale. Multi-omics technologies offer unprecedented resolution of biological processes, but their integration into translational workflows often remains fragmented, resource-intensive, and technically daunting.

That’s where Omics-as-a-Service (OAS) comes in — a new operational paradigm that offers end-to-end omics support as a modular, scalable, and automated solution.

What Is Omics-as-a-Service?

Omics-as-a-Service (OAS) is a service model that provides researchers, biotech companies, and clinical teams with fully managed access to multi-omics capabilities, including:

• Sample logistics and tracking
• Laboratory coordination with certified omics providers
• Automated pipelines for genomics, transcriptomics, proteomics, metabolomics, and beyond
• Standardized quality control and data formatting
• Personalized reports with biologically and clinically interpretable outputs

Instead of building and maintaining omics infrastructure internally, clients outsource complexity — and gain scientific precision.

Why OAS Matters for Translational Medicine

Translational medicine seeks to bridge the gap between basic research and clinical application. But this bridge often breaks down due to fragmented data workflows, siloed platforms, and unclear interpretation pathways. OaaS helps address these challenges by:

1. Streamlining operational workflows
   Coordinating logistics, labs, and data pipelines in one integrated process.
2. Delivering multi-omics depth
   Providing simultaneous access to several molecular layers for richer patient profiling and discovery.
3. Enabling reproducibility
   Ensuring validated methods, standardized protocols, and auditable metadata from sample to insight.
4. Supporting clinical and research decisions
   Producing personalized reports aligned with scientific goals or diagnostic requirements.

Real-World Impact Scenarios

• A hospital consortium investigating long COVID uses OAS to collect blood samples, generate transcriptomic and proteomic data, and identify biomarkers for immune dysregulation.
• A biotech startup working on rare neurological disorders uses OAS to characterize patient cohorts via multi-omics signatures — without having to build in-house data infrastructure.
• A clinical trial team leverages OAS to centralize data collection, standardize assays across labs, and deliver AI-ready datasets for modeling drug response.

The Nexyra OAS Platform

At Nexyra, we’ve designed Omics-as-a-Service to simplify complexity without sacrificing scientific depth. Our offering includes:

• Sample collection and global logistics coordination
• Integration with certified laboratory partners
• High-resolution omics pipelines with customizable parameters
• End-to-end automation and quality control
• Secure data delivery and report generation tailored to each use case
• Compatibility with AI pipelines, biomarker discovery tools, and regulatory standards

Whether you need single-layer transcriptomics or full-scale proteogenomic integration, we build the service around your objective — not the other way around.

Why Choose Nexyra?

• Modular, scalable service architecture
• Full compliance with data privacy and ethics (EU-GDPR, ISO, GCP)
• Interdisciplinary team of scientists, engineers, and biomedical experts
• Fast onboarding, rapid turnaround, and transparent workflows
• Collaboration-ready for research institutions, pharma, and diagnostics

—

Ready to bring your science closer to clinical impact?

Nexyra’s Omics-as-a-Service is built to accelerate your translational goals with precision, speed, and reliability.